

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**VOLUNTARY ANNOUNCEMENT –
JS107 FOR INJECTION RECEIVED THE ACCEPTANCE NOTICE
FOR THE INVESTIGATIONAL NEW DRUG APPLICATION**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 28 December 2021.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, the Company has received the Acceptance Notice (《受理通知書》) issued by the National Medical Products Administration (the “**NMPA**”). The investigational new drug application for the JS107 for injection (project code: “**JS107**”) has been accepted. Relevant information is as follows:

ABOUT JS107

Drug name: JS107 for injection

Application matter: Clinical Trial of Domestic Production Registration of Pharmaceutical Product
Acceptance No.: CXSL2101522

Applicant: Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司)

Review conclusion: Accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China.

JS107 is a recombinant humanised anti-Claudin18.2 monoclonal antibody-MMAE (Monomethyl auristatin E) conjugate for injection self-developed by the Company, which is one of antibody-drug conjugates (“**ADCs**”) targeting the tumor-associated protein Claudin18.2, and is intended to be used for the treatment of advanced malignant tumors, such as gastric cancer and pancreatic cancer. JS107 can bind to Claudin18.2 on the surface of tumor cells, enter the tumor cells through endocytosis, release the small molecule toxin MMAE, and therefore produce powerful killing ability on tumor cells. JS107 can further kill tumor cells by retaining antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects. Also, due to the cell permeability of MMAE, JS107 can mediate the indiscriminate killing of other tumor cells through the bystander effect, thereby improving the efficacy and inhibiting tumor recurrence. Pre-clinical in vivo pharmacodynamics show that JS107 has a significant anti-tumor effect. In addition, JS107 is well tolerated by animals and also has good safety profile.

Moreover, JS012 injection, which is a recombinant humanised anti-Claudin18.2 monoclonal antibody self-developed by the Company, was approved by the NMPA for clinical trials in November 2021. As of the date of this announcement, there is no product with similar target approved for marketing domestically and overseas.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialisation. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development projects and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict accordance with relevant regulations.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 28 December 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.

* For identification purpose only